Sterling Biotech Group

Sterling Biotech Limited is an India-based life sciences manufacturing company historically focused on fermentation-derived active pharmaceutical ingredients and pharmaceutical-grade gelatin. Its disclosed commercial products have included lovastatin, simvastatin ammonium salt, anthracycline oncology APIs such as doxorubicin hydrochloride, daunorubicin hydrochloride, epirubicin hydrochloride, idarubicin hydrochloride, and zoledronic acid, alongside a gelatin division serving pharmaceutical and nutraceutical applications. The company has also been referenced in a 2024 Zydus/Perfect Day transaction announcement as being engaged in fermentation-based API products and gelatine, with plans for a joint venture focused on fermented animal-free protein. However, the listed company itself has been in liquidation since 2022, so it should be treated as a distressed/under-liquidation commercial manufacturer rather than a clinical-stage drug developer. For biotech diligence, Sterling Biotech is best characterized as a manufacturing-led pharma/biotech enterprise with legacy API and gelatin operations rather than an innovation-driven therapeutic pipeline company.